- Home
- VSTM
VSTM
Verastem Inc.
as 11-20-2024 4:00pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 132.0M | IPO Year: | 2012 |
| Target Price: | $14.57 | AVG Volume (30 days): | 950.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $14.22 | Next Earning Date: | 11-06-2024 |
| Revenue: | $10,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 108.05% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Oct 7 '24 | Sell | $2.86 | 6 | $17.16 | 47,461 | |
| Calkins Daniel | VSTM | Chief Financial Officer | Sep 20 '24 | Sell | $2.74 | 93 | $257.04 | 47,461 | |
| Gagnon Robert E. | VSTM | Director | Sep 19 '24 | Sell | $2.79 | 131 | $365.49 | 34,892 | |
| Stuglik Brian M | VSTM | Director | Sep 19 '24 | Sell | $2.79 | 336 | $937.44 | 96,109 | |
| Paterson Dan | VSTM | President and CEO | Sep 19 '24 | Sell | $2.79 | 184 | $513.36 | 232,388 | |
| Gagnon Robert E. | VSTM | Director | Sep 16 '24 | Sell | $2.80 | 287 | $803.60 | 34,892 | |
| Stuglik Brian M | VSTM | Director | Sep 16 '24 | Sell | $2.80 | 600 | $1,680.00 | 96,109 | |
| Paterson Dan | VSTM | President and CEO | Sep 16 '24 | Sell | $2.80 | 246 | $688.80 | 232,388 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
Associated Press Finance
15 days ago
Verastem: Q3 Earnings Snapshot
Business Wire
15 days ago
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Pharmaceutical Technology
20 days ago
Verastem Oncology submits NDA for ovarian cancer treatment
MT Newswires
20 days ago
Verastem Completes Rolling NDA Submission to US FDA for Drug Combination to Treat Rare Ovarian Cancer
Business Wire
21 days ago
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Business Wire
21 days ago
Verastem Oncology to Participate in Upcoming Investor Conferences
MT Newswires
a month ago
Verastem Reports Updated Data on Phase 2 Study of Ovarian Cancer Combination Therapy
Business Wire
a month ago
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.